Evidence map›Paper›PMID 32140553›Full record

ArticleInternational journal of cardiology. Heart & vasculature2020

Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry.

Michele Correale, Adriana Mallardi, Pietro Mazzeo, Lucia Tricarico, Claudia Diella, Valentina Romano, Armando Ferraretti, Alessandra Leopizzi, Giuseppina Merolla, Matteo Di Biase and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Why we need treatment? Prognosis of tricuspid regurgitation.European heart journal supplements : journal of the European Society of Cardiology · 2026
    Article
  7. Article
  8. Review
  9. Management of Tricuspid Valve Regurgitation Consensus Recommendations.Heart views : the official journal of the Gulf Heart Association · 2026
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Michele CorrealeOspedali Riuniti University Hospital, Foggia, Italy.
Adriana MallardiDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Pietro MazzeoDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Lucia TricaricoDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Claudia DiellaDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Valentina RomanoDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Armando FerrarettiCardiology Department, Civic Hospital, Canosa di Puglia, BAT, Italy.
Alessandra LeopizziDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Giuseppina MerollaOspedali Riuniti University Hospital, Foggia, Italy.
Matteo Di BiaseDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Natale Daniele BrunettiDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies and case-series showed improvement in left ventricular (LV) function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We therefore aimed to evaluate whether also right ventricular (RV) function may improve after sacubitril/valsartan therapy.

methodsSixty consecutive patients with chronic heart failure and NYHA class II-III were followed up for 12 months after therapy with sacubitril/valsartan. Left and (RV) function was assessed at baseline and after 12 months of therapy.

resultsAt 12-month control, therapy with sacubitril/valsartan was associated with a significant improvement in a series of echo parameters: LVEF (p < 0.05), LV end-systolic volume (p < 0.01), left atrium area (p < 0.05).Right ventricular echo parameters were also improved after sacubitril/valsartan therapy: PAsP (31.0 ± 12.8 vs 34.7 ± 12.5 mmHg, p < 0.05), TAPSE (17.8 ± 3.9 vs 16.5 ± 4.0 mm, p < 0.001); mean PAsP reduction was 3.7 ± 11.4 mmHg (-6.3 ± 37.7%), mean TAPSE increase 1.3 ± 2.5 mm (+9.5 ± 15.7%).Indexed (%) improvement in PAsP (r 0.33, p < 0.01) and TAPSE (r -0.42, p < 0.01) values were proportional to baseline levels. Improvement in PAsP and TAPSE were independent of left ventricular improvements except for PAsP and end-systolic volumes (r 0.44, p < 0.01).

conclusionsIn a real world scenario, sacubitril/valsartan was associated with an improved RV function.

Indexed as

ARNIChronic heart failureNeprilysin inhibitorsRight ventricular functionSacubitril valsartan

Identifiers

PMID32140553
PMCPMC7044512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.